Carolina Breast Imaging Specialists Adopts iCAD’s Advanced Artificial Intelligence Technology For Digital Breast 3D Tomosynthesis
iCAD’s revolutionary PowerLook® Tomo Detection deep learning solution helps radiologists identify breast cancer more efficiently
GREENVILLE, NC -- June 6, 2017 - Carolina Breast Imaging Specialists of Greenville, North Carolina today announced it is the first US site to begin using iCAD’s (Nasdaq: ICAD) advanced artificial intelligence technology, PowerLook® Tomo Detection, in conjunction with GE Healthcare’s tomosynthesis platform. PowerLook Tomo Detection is a first-of-its-kind, concurrent-read cancer detection solution for Digital Breast Tomosynthesis (DBT) and is engineered to make it possible for radiologists to detect breast cancer more efficiently.
Medical facilities worldwide are increasingly adopting DBT technology for screening and diagnostic mammography. Tomosynthesis produces hundreds of images compared to 2D full field digital mammography which typically produces four images. With DBT, radiologists may have to spend significantly more time to review and interpret each exam. The PowerLook Tomo Detection deep learning algorithm automatically analyzes each slice in the tomosynthesis data set, supporting radiologists in identifying suspicious areas with greater speed and precision. Suspicious areas identified by PowerLook Tomo Detection are blended by GE Healthcare’s Seno Iris® workstation into the 2D synthetic image to provide radiologists with a single enhanced image, known as the Enhanced V-Preview image.
“More and more medical facilities are recognizing the benefits of tomosynthesis. It provides a more comprehensive view of each patient’s breast tissue compared to traditional 2D digital mammography, but the larger data sets produced by DBT can be challenging for radiologists,” said Bruce Schroeder, MD, Medical Director, Carolina Breast Imaging Specialists. “The Enhanced V-Preview image created by iCAD’s PowerLook Tomo Detection solution and GE Healthcare’s Seno Iris workstation allow radiologists to detect breast cancer in patients more efficiently without compromising clinical performance.”
In a US clinical study conducted in 2016, radiologists were able to significantly reduce review time when reading 3D tomosynthesis exams with PowerLook Tomo Detection. The study included 20 radiologists reading 240 tomosynthesis cases both with and without the PowerLook Tomo Detection technology. Reading time was reduced by up to 37% with an average reduction of 29% when using PowerLook Tomo Detection, with no statistically significant impact on sensitivity, specificity or recall rate. PowerLook Tomo Detection received FDA approval in March 2017 and is CE Marked in the European Union and licensed by Health Canada.
“We are excited to be the first facility in the US to offer this innovative solution,” continued Dr. Schroeder. “In using PowerLook Tomo Detection we have already seen the benefits for radiologists where we can now review the expansive tomosynthesis image sets more effectively. This allows us to spend our time analyzing abnormalities and consulting with our patients.”
In addition to Carolina Breast Imaging Specialists, iCAD expects multiple other facilities in the US to adopt PowerLook Tomo Detection in the coming months.
About Carolina Breast Imaging Specialists, PLLC
Carolina Breast Imaging Specialists and Dr. Schroeder are known nationally and internationally for their innovation and expertise in the field of breast imaging, and in particular 3D mammography (tomosynthesis). Dr. Schroeder and his staff have decades of experience in breast cancer care and offer the only practice in their region dedicated exclusively to breast imaging and interventions. For more information visit www.CBISpecialists.com
About iCAD, Inc.
iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit or www.icadmed.com or www.xoftinc.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “would”, “could”, “consider”, “project”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, including the 10-K for the year ended December 31, 2016, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
For iCAD investor relations:
Bob Yedid, (646)-597-6989
For iCAD media inquiries:
Berry & Company Public Relations, LLC
Lynn Granito, 212-253-8881
Sales & Services
+1 866 280 2239